Zenas BioPharma to Present at the Guggenheim SMID Cap Biotech Conference

Rhea-AI Summary

Zenas BioPharma (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company focused on immunology-based therapies, has announced its participation in the Guggenheim SMID Cap Biotech Conference. The company's management will engage in a fireside chat presentation scheduled for Wednesday, February 5, 2025, at 3:00 p.m. ET.

Interested parties can access both the live webcast and archived replay of the presentation through the 'Events and Presentations' section within the Investor & Media Relations area of the Zenas BioPharma website.

WALTHAM, Mass., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies, today announced management’s fireside chat presentation at the Guggenheim SMID Cap Biotech Conference on Wednesday, February 5, 2025, at 3:00 p.m. ET.

A live webcast and archived replay of the Company’s presentation can be accessed under “Events and Presentations” in the Investor & Media Relations section of the Zenas BioPharma website.

About Zenas BioPharma, Inc.

Zenas is a clinical-stage global biopharmaceutical company committed to becoming a leader in the development and commercialization of transformative immunology-based therapies for patients in need. Our core business strategy combines our experienced leadership team with a disciplined product candidate acquisition approach to identify, acquire and develop product candidates globally that we believe can provide superior clinical benefits to patients living with autoimmune diseases. Zenas’ lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. We believe that obexelimab’s unique mechanism of action and self-administered, subcutaneous injection regimen may broadly and effectively address the pathogenic role of B cell lineage in chronic autoimmune disease. For more information about Zenas BioPharma, please visit www.zenasbio.com and follow us on LinkedIn.

The Zenas BioPharma word mark and logos are trademarks of Zenas BioPharma, Inc. or its affiliated companies.

Investor Contact:

Matthew Osborne

Investor Relations and Corporate Communications
Matt.osborne@zenasbio.com

Media Contact:
Argot Partners

Zenas@argotpartners.com

FAQ

When is Zenas BioPharma (ZBIO) presenting at the Guggenheim SMID Cap Biotech Conference 2025?

Zenas BioPharma (ZBIO) is scheduled to present at the Guggenheim SMID Cap Biotech Conference on Wednesday, February 5, 2025, at 3:00 p.m. ET.

How can investors watch Zenas BioPharma's (ZBIO) Guggenheim Conference presentation?

Investors can watch both the live webcast and archived replay of the presentation through the 'Events and Presentations' section in the Investor & Media Relations area of the Zenas BioPharma website.

What type of presentation will ZBIO deliver at the Guggenheim SMID Cap Biotech Conference?

ZBIO management will participate in a fireside chat presentation format at the Guggenheim SMID Cap Biotech Conference.

Where will the archived replay of ZBIO's Guggenheim Conference presentation be available?

The archived replay will be available in the 'Events and Presentations' section under Investor & Media Relations on the Zenas BioPharma website.